Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GLP1R | P43220 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12250798 | 0.78 | NOS3 (0.42) | NOS3NOS1NOS2KMT2AGLP1R | |
| SCHEMBL1179081 | 0.78 | HCAR3 (0.42) | S1PR1KMT2A | |
| SCHEMBL12810688 | 0.77 | NOS3 (0.36) | S1PR1NOS3NOS1NOS2KMT2A | |
| SCHEMBL16158780 | 0.75 | GLP1R (0.41) | NOS3NOS1NOS2KMT2AGLP1R | |
| SCHEMBL21736826 | 0.71 | NOS3 (0.37) | NOS3NOS1NOS2KMT2AAPLNR | |
| SCHEMBL12240485 | 0.69 | NOS3 (0.42) | NOS3NOS1NOS2KMT2ASMN1; SMN2 | |
| SCHEMBL20321338 | 0.67 | NOS3 (0.41) | NOS3NOS1NOS2KMT2ASMN1; SMN2 | |
| SCHEMBL21016450 | 0.66 | NOS3 (0.39) | NOS3NOS1NOS2KMT2ASMN1; SMN2 | |
| SCHEMBL22564851 | 0.66 | NOS3 (0.39) | NOS3NOS1NOS2KMT2ASMN1; SMN2 | |
| SCHEMBL31587245 | 0.66 | NOS3 (0.56) | NOS3NOS1NOS2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212998-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| US-20110212998-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| US-20110046170-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-24 | — | — | US | disclosed |
| US-20110046170-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-24 | — | — | US | disclosed |
| WO-2009109907-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009024905-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046170-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | TYMP, DPYD, ENTPD5 | S1PR1 766/4885NOS3 2507/4885NOS1 2770/4885 |
| US-20110212998-A1 | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885NOS3 2145/4885NOS1 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.